Analyses of gene expression profiles in the T cell-inflamed microenvironment have shown pan-tumor immune-related signatures that correlate with anti–PD-1 benefit, including IFNγ-responsive genes related to antigen presentation, chemokines, cytolytic activity, and adaptive immune resistance [73]. This evidence concerns the gene PDCD1 and neoplasm.